Less than a year after landing a multibillion-dollar deal expansion with partner Gilead Sciences Inc., targeted cancer drug developer Tango Therapeutics Inc. is making moves to go public via a merger with Boxer Capital LLC-sponsored special purpose acquisition company BCTG Acquisition Corp.
Ventus Therapeutics Inc. closed a $100 million series B round less than 12 months after raising $60 million in series A funding, to continue development of several preclinical programs informed by novel insights into the structural biology of key targets associated with innate immune signal pathways implicated in a wide range of disease areas.
Theseus Pharmaceuticals Inc., a startup developing new tyrosine kinase inhibitors to overcome treatment-resistant cancer mutations, has raised $100 million in a series B financing led by Foresite Capital. Co-founded at the health care investment firm Orbimed with former Ariad Pharmaceuticals Inc. scientists who pioneered the development of pan-variant kinase inhibitors, the company's lead candidate is THE-630, a next-generation pan-variant KIT inhibitor for the potential treatment of refractory gastrointestinal stromal tumors.
The newly renamed Hutchmed (China) Ltd., previously known as Hutchison China Meditech Ltd. (Chi-Med), plans to sell $100 million of its American depository shares at $30.50 per ADS in a private placement to funds affiliated with Baring Private Equity Asia.
HONG KONG – Onquality Pharmaceuticals LLC raised an additional $20 million from a series A+ financing round, bringing its amount of capital raised to $35 million.
RSS
